Results 31 to 40 of about 3,619 (165)

Differential Influence of Pueraria lobata Root Extract and Its Main Isoflavones on Ghrelin Levels in Alcohol-Treated Rats

Pharmaceuticals, 2021
The study was carried out on alcohol-preferring male Wistar rats. The following drugs were repeatedly (28×) administered: acamprosate (500 mg/kg, p.o.), naltrexone (0.1 mg/kg, i.p), and Pueraria lobata (kudzu) root extract (KU) (500 mg/kg, p.o.) and its ...
Michał Szulc, Radosław Kujawski, Justyna Baraniak, Małgorzata Kania-Dobrowolska, Ewa Kamińska, Agnieszka Gryszczyńska, Kamila Czora-Poczwardowska, Hanna Winiarska, Przemysław Ł. Mikołajczak   +8 more
doaj   +1 more source

Acamprosate Suppresses Ethanol-Induced Place Preference in Mice With Ethanol Physical Dependence

Journal of Pharmacological Sciences, 2013
The present study investigated the effect of acamprosate on ethanol (EtOH)-induced place preference in mice with EtOH physical dependence. The expression of EtOH (2 g/kg, intraperitoneally)-induced place preference in mice without EtOH treatment before ...
Kazuhiro Kurokawa, Koji Mizuno, Masahiro Shibasaki, Masaya Higashioka, Michiko Oka, Masaaki Hirouchi, Seitaro Ohkuma   +6 more
doaj   +1 more source

Neuroprotective role of acamprosate and rasagiline in epilepsy: In silico and in vivo study [PDF]

Scripta Medica
Background/Aim: Current treatments for epilepsy have only indicative relief without smashing the pathological trademarks of the disease. The unmet need is to find new therapeutic active drug candidates for effective management of epilepsy and associated ...
Kumar Sandeep, Singh Govind, Chhikara Manisha, Shukla Sunil, Khatri Ramchander, Dar Mohammad Ovais, Lather Amit, Hooda Tanuj   +7 more
doaj   +1 more source

The control of abstinence in the treatment of alcohol dependence: the use of acamprosate in relapse prevention

Journal of Biological Research, 2014
Treatment with acamprosate is a valid tool to complement psychotherapy as it does not cause addiction, abuse or withdrawal of its suspension and does not interfere with other medications that patients often alcoholics must take.
Fabio Venturella, Anna Asaro, Guido Faillace, Gianpaolo Spinnato, Danila Di Majo, Maurizio La Guardia, Marco Giammanco, Stefania Aiello   +7 more
doaj   +1 more source

Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT

Health Technology Assessment, 2023
Background Acamprosate is an effective and cost-effective medication for alcohol relapse prevention but poor adherence can limit its full benefit. Effective interventions to support adherence to acamprosate are therefore needed.
Kim Donoghue, Sadie Boniface, Eileen Brobbin, Sarah Byford, Rachel Coleman, Simon Coulton, Edward Day, Ranjita Dhital, Anum Farid, Laura Hermann, Amy Jordan, Andreas Kimergård, Maria-Leoni Koutsou, Anne Lingford-Hughes, John Marsden, Joanne Neale, Aimee O’Neill, Thomas Phillips, James Shearer, Julia Sinclair, Joanna Smith, John Strang, John Weinman, Cate Whittlesea, Kideshini Widyaratna, Colin Drummond   +25 more
doaj   +1 more source

Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements

The Milbank Quarterly, EarlyView.
Policy Points States contract with Medicaid managed care plans to administer benefits for roughly 70 million Medicaid enrollees, yet little is known about how plan benefit policies for substance use disorder (SUD) treatment medications align with state requirements.
SAGE R. FELTUS, CHRISTINA M. ANDREWS, LAUREN PETERSON, COLLEEN M. GROGAN, AMANDA J. ABRAHAM, OLIVIA M. HINDS, MAUREEN T. STEWART   +6 more
wiley   +1 more source

Alcohol abuse and related disorders treatment of alcohol dependence

Неврология, нейропсихиатрия, психосоматика, 2014
Alcohol abuse and alcoholism are the leading causes of worse health and increased mortality rates. Excessive alcohol consumption is the third leading cause of the global burden of diseases and a leading factor for lower lifespan and higher mortality ...
Yu. P. Sivolap
doaj   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis

Frontiers in Pharmacology, 2019
Background: Sleep disorders are commonly associated with acute and chronic use of alcohol and with abstinence. To date, there are four approved drugs to treat alcohol use disorder (AUD): disulfiram, acamprosate, naltrexone, and nalmefene.
Francesca Panin, Alessandra T. Peana
doaj   +1 more source